IJCEP Copyright © 2007-All rights reserved.
Int J Clin Exp Pathol 2013;6(12):2904-2911

Original Article
Decreased expression of miR-218 is associated with poor prognosis in patients with
colorectal cancer

Hong Yu, Guangzhong Gao, Lin Jiang, Lingchuan Guo, Mei Lin, Xiao Jiao, Weiguang Jia, Junxing Huang

Departments of Pathology, Neurosurgery, Anesthesiology, Oncology, Cardiothoracic Surgery, Taizhou People’s Hospital, Jiangsu, China;
Department of Pathology, The First Affiliated Hospital of Soochow University, Jiangsu, China. Equal contributors.

Received October 15, 2013; Accepted November 10, 2013; Epub November 15, 2013; Published December 1, 2013

Abstract: The identification of biomarkers in colorectal cancer (CRC) diagnosis and therapy is important in achieving early cancer diagnosis
and improving patient outcomes. The aim of this study was to examine clinical significance of miR-218 expression in sera and tissues from
CRC patients. A total of 189 cases and 30 healthy subjects were included. The expression levels of miR-218, SLIT2 and SLIT3 were measured
by quantitative reverse transcription PCR (qRT-PCR). The relationship between miR-218 expression and clinicopathological characteristics
was investigated. The expression levels of miR-218, SLIT2 and SLIT3 in CRC tissues were decreased than those in adjacent normal tissues
(all P < 0.05). miR-218 expression was significantly associated with TNM stage, lymph node metastasis (LNM) and differentiation (all P < 0.05).
Patients with low miR-218 expression had shorter survival time than those with high miR-218 expression (P = 0.036). Furthermore, the
expression levels of serum miR-218 in CRC patients were lower than those in controls (P = 0.005). An increased level of serum miR-218 was
found 1 month after surgery (P = 0.026). In conclusion, the miR-218 may has important roles in the development and progression of CRC and
be a potential diagnostic and prognostic biomarker of CRC. (IJCEP1310038).

Keywords: Colorectal cancer, miR-218, microRNA, survival, expression

Address correspondence to: Dr. Junxing Huang, Department of Oncology, Taizhou People’s Hospintal, 210 Yingchun Road, Taizhou, Jiangsu
225300, China. Tel: +86 523 86333483; Fax: +86 523 86333483; E-mail: hjxtz@sina.cn; hjxtz@outlook.com